Work

Final Results of a Phase 3 Trial of Celecoxib (C) in Addition to Standard Chemotherapy for Advanced Non–Small Cell Lung Cancer With COX- 2 Overexpression: CALGB 30801 (Alliance)

Year: 2017

Type: article

Source: International Journal of Radiation Oncology*Biology*Physics

DOI: 10.1016/j.ijrobp.2017.01.038

Authors: M.J. Edelman, X. Wang, L. Hodgson, R.T. Cheney, M.Q. Baggstrom, T. Sachdev, A. Gajra, E.M. Bertino, K.L. Reckamp, J. Molina, J. Schiller, K. Mitchell-Edwards, P. Friedman, J. Ritter, G. Milne, T.E. Stinchcombe, O. Hahn, E.E. Vokes

Institutions: University of Maryland, Baltimore, Duke University, Roswell Park Comprehensive Cancer Center, Washington University in St. Louis, SUNY Upstate Medical University, The Ohio State University, City Of Hope National Medical Center, Mayo Clinic, The University of Texas Southwestern Medical Center, Yale University, University of Chicago, University of Minnesota, Vanderbilt University, University of North Carolina at Chapel Hill, UNC Lineberger Comprehensive Cancer Center

Language: English

Topic: Inflammatory mediators and NSAID effects

Subfield: Pharmacology (medical)

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2607235967

FWCI:

Cites:

Cited by:

Related to: 10